 | • レポートコード：MRC2304L091 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、232ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療機器 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社は、2021年に2,391.23百万ドルであった世界の臨床試験機器＆補助ソリューション市場規模が、2022年に2,581.57百万ドルへと拡大し、その後CAGR 8.21％で成長して2027年までに3,840.12百万ドルに達すると予測しています。当書は、臨床試験機器＆補助ソリューションの世界市場を総合的に分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、製品別（サービス、ソーシング、供給/物流）分析、種類別（生物製剤、医療機器、小分子）分析、治療領域別（血液疾患、心血管疾患、中枢神経系＆精神障害、消化器疾患、免疫疾患）分析、最終用途別（受託研究機関（CRO）、医療機器メーカー、製薬＆バイオテクノロジー企業）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などの項目をまとめています。なお、当書に掲載されている企業情報には、Almac Group Limited、Ancillare, LP、Avantor, Inc.、Emsere B.V.、Eurofins Scientific、Imperial Clinical Research Services, Inc.、IRM Europe、Marken, a UPS Company、Myonex, Inc.、Parexel International Corporation、Piramal Pharma Solutionsなどが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の臨床試験機器＆補助ソリューション市場規模：製品別 - サービスの市場規模 - ソーシングの市場規模 - 供給/物流の市場規模 ・世界の臨床試験機器＆補助ソリューション市場規模：種類別 - 生物製剤の市場規模 - 医療機器の市場規模 - 小分子の市場規模 ・世界の臨床試験機器＆補助ソリューション市場規模：治療領域別 - 血液疾患における市場規模 - 心血管疾患における市場規模 - 中枢神経系＆精神障害における市場規模 - 消化器疾患における市場規模 - 免疫疾患における市場規模 ・世界の臨床試験機器＆補助ソリューション市場規模：最終用途別 - 受託研究機関（CRO）における市場規模 - 医療機器メーカーにおける市場規模 - 製薬＆バイオテクノロジー企業における市場規模 ・世界の臨床試験機器＆補助ソリューション市場規模：地域別 - 南北アメリカの臨床試験機器＆補助ソリューション市場規模 アメリカの臨床試験機器＆補助ソリューション市場規模 カナダの臨床試験機器＆補助ソリューション市場規模 ブラジルの臨床試験機器＆補助ソリューション市場規模 ... - アジア太平洋の臨床試験機器＆補助ソリューション市場規模 日本の臨床試験機器＆補助ソリューション市場規模 中国の臨床試験機器＆補助ソリューション市場規模 インドの臨床試験機器＆補助ソリューション市場規模 韓国の臨床試験機器＆補助ソリューション市場規模 台湾の臨床試験機器＆補助ソリューション市場規模 ... - ヨーロッパ/中東/アフリカの臨床試験機器＆補助ソリューション市場規模 イギリスの臨床試験機器＆補助ソリューション市場規模 ドイツの臨床試験機器＆補助ソリューション市場規模 フランスの臨床試験機器＆補助ソリューション市場規模 ロシアの臨床試験機器＆補助ソリューション市場規模 ... - その他地域の臨床試験機器＆補助ソリューション市場規模 ・競争状況 ・企業情報 |
The Global Clinical Trial Equipment & Ancillary Solutions Market size was estimated at USD 2,391.23 million in 2021 and expected to reach USD 2,581.57 million in 2022, and is projected to grow at a CAGR 8.21% to reach USD 3,840.12 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Clinical Trial Equipment & Ancillary Solutions to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Product, the market was studied across Service, Sourcing, and Supply/Logistics. The Service is further studied across Calibrations and Equipment Servicing. The Sourcing is further studied across Procurement and Rental. The Supply/Logistics is further studied across Packaging and Transportation.
Based on Type, the market was studied across Biologic Drugs, Medical Devices, and Small Molecules.
Based on Phase, the market was studied across Phase I, Phase II, Phase III, and Phase IV.
Based on Therapeutic Area, the market was studied across Blood Disorders, Cardiovascular Diseases, Cns & Mental Disorders, Digestive Disorders, Immunology, Infectious Diseases, Metabolic Disorders, and Oncology.
Based on End use, the market was studied across Contract Research Organizations (CROs), Medical Devices Companies, and Pharmaceutical & Biotechnology companies.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Clinical Trial Equipment & Ancillary Solutions market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Clinical Trial Equipment & Ancillary Solutions Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Clinical Trial Equipment & Ancillary Solutions Market, including Almac Group Limited, Ancillare, LP, Avantor, Inc., Emsere B.V., Eurofins Scientific, Imperial Clinical Research Services, Inc., IRM Europe, Marken, a UPS Company, Myonex, Inc., Parexel International Corporation, Piramal Pharma Solutions, Quipment SAS, Recipharm AB, Thermo Fisher Scientific, Inc., and Woodley Equipment Company Ltd..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Clinical Trial Equipment & Ancillary Solutions Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Clinical Trial Equipment & Ancillary Solutions Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Clinical Trial Equipment & Ancillary Solutions Market?
4. What is the competitive strategic window for opportunities in the Global Clinical Trial Equipment & Ancillary Solutions Market?
5. What are the technology trends and regulatory frameworks in the Global Clinical Trial Equipment & Ancillary Solutions Market?
6. What is the market share of the leading vendors in the Global Clinical Trial Equipment & Ancillary Solutions Market?
7. What modes and strategic moves are considered suitable for entering the Global Clinical Trial Equipment & Ancillary Solutions Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing government expenditure in healthcare industry worldwide
5.1.1.2. Rising emergence of new and rare disorders
5.1.1.3. Outsourcing of clinical trial activity across the globe
5.1.2. Restraints
5.1.2.1. Elevation in cost of drug development and clinical trials
5.1.3. Opportunities
5.1.3.1. Proliferation in numbers of regulatory approvals with favorable governmental support
5.1.3.2. Rise in the number of CRO and pharmaceutical & medical companies
5.1.4. Challenges
5.1.4.1. Complexities in procedures of cross border logistics challenging clinical trials
5.2. Cumulative Impact of COVID-19
6. Clinical Trial Equipment & Ancillary Solutions Market, by Product
6.1. Introduction
6.2. Service
6.3.1. Calibrations
6.3.2. Equipment Servicing
6.3. Sourcing
6.4.1. Procurement
6.4.2. Rental
6.4. Supply/Logistics
6.5.1. Packaging
6.5.2. Transportation
7. Clinical Trial Equipment & Ancillary Solutions Market, by Type
7.1. Introduction
7.2. Biologic Drugs
7.3. Medical Devices
7.4. Small Molecules
8. Clinical Trial Equipment & Ancillary Solutions Market, by Phase
8.1. Introduction
8.2. Phase I
8.3. Phase II
8.4. Phase III
8.5. Phase IV
9. Clinical Trial Equipment & Ancillary Solutions Market, by Therapeutic Area
9.1. Introduction
9.2. Blood Disorders
9.3. Cardiovascular Diseases
9.4. Cns & Mental Disorders
9.5. Digestive Disorders
9.6. Immunology
9.7. Infectious Diseases
9.8. Metabolic Disorders
9.9. Oncology
10. Clinical Trial Equipment & Ancillary Solutions Market, by End use
10.1. Introduction
10.2. Contract Research Organizations (CROs)
10.3. Medical Devices Companies
10.4. Pharmaceutical & Biotechnology companies
11. Americas Clinical Trial Equipment & Ancillary Solutions Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Clinical Trial Equipment & Ancillary Solutions Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Clinical Trial Equipment & Ancillary Solutions Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.1.1. Quadrants
14.1.2. Business Strategy
14.1.3. Product Satisfaction
14.2. Market Ranking Analysis, By Key Player
14.3. Market Share Analysis, By Key Player
14.4. Competitive Scenario
14.4.1. Merger & Acquisition
14.4.2. Agreement, Collaboration, & Partnership
14.4.3. New Product Launch & Enhancement
14.4.4. Investment & Funding
14.4.5. Award, Recognition, & Expansion
15. Company Usability Profiles
15.1. Almac Group Limited
15.1.1. Business Overview
15.1.2. Key Executives
15.1.3. Product & Services
15.2. Ancillare, LP
15.2.1. Business Overview
15.2.2. Key Executives
15.2.3. Product & Services
15.3. Avantor, Inc.
15.3.1. Business Overview
15.3.2. Key Executives
15.3.3. Product & Services
15.4. Emsere B.V.
15.4.1. Business Overview
15.4.2. Key Executives
15.4.3. Product & Services
15.5. Eurofins Scientific
15.5.1. Business Overview
15.5.2. Key Executives
15.5.3. Product & Services
15.6. Imperial Clinical Research Services, Inc.
15.6.1. Business Overview
15.6.2. Key Executives
15.6.3. Product & Services
15.7. IRM Europe
15.7.1. Business Overview
15.7.2. Key Executives
15.7.3. Product & Services
15.8. Marken, a UPS Company
15.8.1. Business Overview
15.8.2. Key Executives
15.8.3. Product & Services
15.9. Myonex, Inc.
15.9.1. Business Overview
15.9.2. Key Executives
15.9.3. Product & Services
15.10. Parexel International Corporation
15.10.1. Business Overview
15.10.2. Key Executives
15.10.3. Product & Services
15.11. Piramal Pharma Solutions
15.11.1. Business Overview
15.11.2. Key Executives
15.11.3. Product & Services
15.12. Quipment SAS
15.12.1. Business Overview
15.12.2. Key Executives
15.12.3. Product & Services
15.13. Recipharm AB
15.13.1. Business Overview
15.13.2. Key Executives
15.13.3. Product & Services
15.14. Thermo Fisher Scientific, Inc.
15.14.1. Business Overview
15.14.2. Key Executives
15.14.3. Product & Services
15.15. Woodley Equipment Company Ltd.
15.15.1. Business Overview
15.15.2. Key Executives
15.15.3. Product & Services
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing